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ABSTRACT
Renal metabolism by UDP-glucuronosyltransferase (UGT) enzymes
is central to the clearance of many drugs. However, significant
discrepancies about the relative abundance and activity of individual
UGT enzymes in the normal kidney prevail among reports, whereas
glucuronidation in tumoral kidney has not been examined. In this
study, we performed an extensive profiling of glucuronidation meta-
bolism in normal (n = 12) and tumor (n = 14) kidneys using targeted
mass spectrometry quantification of human UGTs. We then corre-
lated UGT protein concentrations with mRNA levels assessed by
quantitative polymerase chain reaction and with conjugation activity
for the major renal UGTs. Beyond the wide interindividual variability
in expression levels observed among kidney samples, UGT1A9,
UGT2B7, and UGT1A6 are the most abundant renal UGTs in both
normal and tumoral tissues based on protein quantification. In
normal kidney tissues, only UGT1A9 protein levels correlated with
mRNA levels, whereas UGT1A6, UGT1A9, and UGT2B7 quantification
correlated significantly with their mRNA levels in tumor kidneys. Data
support that posttranscriptional regulation of UGT2B7 and UGT1A6
expression is modulating glucuronidation in the kidney. Importantly,
our study reveals a significant decreased glucuronidation capacity of
neoplastic kidneys versus normal kidneys that is paralleled by
drastically reduced UGT1A9 and UGT2B7 mRNA and protein
expression. UGT2B7 activity is the most repressed in tumors relative
to normal tissues, with a 96-fold decrease in zidovudine metabolism,
whereas propofol and sorafenib glucuronidation is decreased by 7.6-
and 5.2-fold, respectively. Findings demonstrate that renal drug
metabolism is predominantly mediated by UGT1A9 and UGT2B7 and
is greatly reduced in kidney tumors.
Introduction
Kidneys mediate excretion of polar drugs and metabolites through
urine and are an important site of inactivation of drugs, hormones,
lipids, and other endogenous compounds (Anders, 1980; Shipkova
et al., 2001; Gaganis et al., 2007; Chu et al., 2009). The contribution
of renal UDP-glucuronosyltransferases (UGTs) to the maintenance of
renal homeostasis and metabolic drug clearance is increasingly
appreciated (Chu et al., 2009; Knights and Miners, 2010; Gundert-
Remy et al., 2014). Renal conjugation contributes to the clearance of
many drugs, including the nonsteroidal anti-inflammatory drugs such
as S-naproxen and ibuprofen, the GABAA receptor agonist and sleeping
aid gaboxadol, the anesthetic propofol, and the immunosuppressant
drug mycophenolic acid (MPA). Other studies further support that
renal glucuronidation surpasses that in the liver for the clearance of
propofol, gaboxadol, MPA, and several other drugs (McGurk et al.,
1998; Gaganis et al., 2007; Knights et al., 2013).
The expression of UGTs by liver and kidney tissues is variable. Of
the 19 documented UGT enzymes, 13 are appreciably expressed in the
liver, the main site of glucuronidation of drugs, whereas only 4 are
documented to be significantly expressed in the kidney (Knights and
Miners, 2010; Guillemette et al., 2014). These observations are based
on polymerase chain reaction (PCR) quantification of mRNAs (Sutherland
et al., 1993; McGurk et al., 1998; Nakamura et al., 2008; Ohno and
Nakajin, 2009; Court et al., 2012), immunohistochemistry detection of
UGTs (Gaganis et al., 2007; Bellemare et al., 2011), assessment of
conjugation activity toward specific substrates (Gaganis et al., 2007;
Chu et al., 2009; Menard et al., 2013), and more recently quantification
of UGT proteins by targeted proteomics (Harbourt et al., 2012; Sato
et al., 2012; Fallon et al., 2013a,b; Sato et al., 2014). UGT1A9 and
UGT2B7 appear as the major UGTs expressed in the kidney. A num-
ber of other UGTs are expressed at lower levels, including UGT1A5,
UGT1A6, UGT1A7, and UGT2B4, but conflicting results have arisen
from different quantification methods (reviewed by Knights and
Miners, 2010). In situ analysis of UGT1A and UGT2B7 expression
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has exposed a heterogeneous localization of renal expression, with
strongest expression in the proximal convoluted tubules. Additionally,
strong to weak expression has been documented in the cortex and
medulla. Only the glomerulus and Bowman’s capsule are devoid of UGT
expression (Gaganis et al., 2007; Bellemare et al., 2011). Develop-
mental stage and disease state further affect UGT expression in tissues,
and this has was recently documented in the kidney (Menard et al.,
2013). Indeed, fetal and tumor kidney tissues display a differential
expression pattern for UGT2B7 caused by the differential usage of al-
ternate promoters (Menard et al., 2013). Despite these several studies,
none have been conducted to systematically compare UGT mRNA
and protein expression and their relationship to enzyme activity.
It was therefore the goal of this study to address UGT mRNA and
protein expression profiles in normal and tumoral kidney tissues and
determine their value as predictors of drug metabolizing capacity by
correlating expression levels with glucuronidation activity using probe
substrates. The glucuronidation profiles of 26 discrete kidneys samples
(12 normal and 14 tumoral) were established by targeted protein quan-
tification, mRNA quantification, and glucuronidation activity to reveal
important contributions of UGT1A9, UGT2B7, and UGT1A6 in the
normal kidney. However, drastically reduced UGT expression and
function were revealed in kidney tumors.
Materials and Methods
Tissue Collections and Homogenates. Normal (n = 12) and neoplastic
(adenocarcinoma, clear cell) kidney samples (n = 14) from male and female
subjects, including nine matched normal peritumoral and tumor pairs, were
obtained from the Tissue Procurement services at the University of North
Carolina Lineberger Comprehensive Cancer Center (Chapel Hill, NC) and have
been described (Menard et al., 2013). All subjects provided written consent for
the use of their tissues for experimental purposes, and the Institutional Review
Board approved the project. Kidney homogenates were prepared in phosphate-
buffered saline containing 0.5 mM dithiothreitol as described below and protein
concentration was determined by a bicinchoninic acid assay (ThermoFisher
Scientific, Ottawa, ON, Canada).
Absolute Quantification by Multiple Reaction Monitoring. Fourteen
UGT1A and UGT2B proteins were quantified using targeted quantitative
proteomics as described (Fallon et al., 2013b). Signature peptides are given in
Supplemental Table 1. All UGTs were quantified with the exception of
UGT2B11, UGT2B28, and UGT2As for which specific signature peptides are not
available. Before quantification, kidney homogenates were diluted to ;10 mg/ml
with phosphate-buffered saline/0.5 mM dithiothreitol and then further diluted
with 50 mM ammonium bicarbonate to 1 mg/ml. For all samples except one,
20 mg of homogenized proteins was denatured, reduced, carbamidomethylated, and
then digested with trypsin (Fallon et al., 2013b); 18 mg of homogenized proteins
was used for the additional sample. Quantification was also assessed in two
commercial protein lysates of paired normal and tumoral kidney tissues purchased
from Oncogene (Rockville, MD), similarly diluted and digested. A mixture of
stable isotope labeled standard peptides (Thermo Biopolymers, Ulm, Germany)
corresponding to the selected signature peptides of each UGT was added to each
sample. Quantitative analysis was achieved on a nanoACQUITY binary pump
system coupled to a QTRAP 5500 mass spectrometer (ABSCIEX, Framingham,
MA), using two multiple reaction monitoring transitions to quantify each UGT,
as described recently (Fallon et al., 2013b) (Supplemental Table 1). Limit of
detection was 0.2 pmol/mg proteins for all UGTs with the exception of UGT1A9,
for which it was 1.0 pmol/mg protein.
Quantification of UGT1A and UGT2B7 mRNAs by Quantitative PCR.
Total RNA from 25–35 mg kidney tissue was extracted using TriReagent and
following recommendation of the manufacturer (Sigma-Aldrich, St. Louis, MO).
The integrity of all RNA samples was verified using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA), and those with an RNA integrity
number above 6 were used for further analysis. cDNA was synthesized from 1 mg
total RNA using Superscript III (Life Technologies, Burlington, ON, Canada) and
125 pmol p(dN)6 random hexamers (Roche Diagnostics, Laval, QC, Canada).
Quantitative PCR reactions were conducted in triplicates in an ABI7000 thermal
cycler (Life Technologies) with 12.5 ng cDNA in a final volume of 15 ml
containing 7.5 ml Sybr Green PCR Master Mix and 125–200 nM primers (Life
Technologies). Cycling conditions were as follows: 10 minutes, 95C; 40 cycles
of 95C for 15 seconds, 58–60C for 1 minute; final melting curve of 95C for 15
seconds, 60C for 1 minute, and 95C for 15 seconds. The list of primer pairs and
specific amplification conditions are given in Supplemental Table 2. Quantitative
PCR data for each UGT (CtUGT) were normalized with 36B4 as an internal
Fig. 1. Expression profiles of UGTs in normal and tumoral kidneys. (A) Absolute
quantification of protein concentrations determined by multiple reaction monitoring
in normal (n = 10) and tumoral (n = 11) kidney homogenates. (B) Relative
expression of UGT mRNA levels established by reverse transcription-quantitative
PCR in normal (n = 11) and tumoral (n = 12) kidneys. mRNA quantification of
UGTs used a general strategy enabling amplification of all known variants.
N, normal kidneys (s); T, tumoral kidneys (d). Mean protein concentrations (pmol/mg
proteins) and mRNA relative quantification (106) of each UGT are given below the
graph, as well as coefficients of variation (CV) among normal and tumoral samples.
Detailed quantification data are given in Tables 1 and 2. **, P#0.01.
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amplification standard (CtUGT 2 Ct36B4 = DCtUGT), and were then normalized
with DCt values (DCtLow) of the sample expressing lowest levels of UGTs to
determine DDCtUGT. The relative quantification was determined using the
equation 22DDCtUGT, as described (Livak and Schmittgen, 2001).
Glucuronidation Activity. Glucuronidation assays were conducted on
kidney tissue homogenates with a panel of UGT probe substrates: bilirubin,
deferiprone [3-hydroxy-1,2-dimethylpyridin-4(1H)-one], propofol (diisopro-
pylphenol), and zidovudine (azidothymidine, AZT) were from Sigma-Aldrich,
mycophenolic acid was from MP Biomedicals (Solon, OH), tacrolimus was
from Cell Signaling Technologies (Danvers, MA), and sorafenib (4-[4-[[4-
chloro-3-(trifluoromethyl)phenyl]carbamoylamino] phenoxy]-N-methyl-pyridine-2-
carboxamide) was from Toronto Research Chemicals (Toronto, ON, Canada).
Glucuronidation assays were performed in triplicate as described (Lepine et al.,
2004; Benoit-Biancamano et al., 2009). Briefly, each enzymatic assay was
conducted in a final volume of 100 ml and contained kidney tissue homogenates
corresponding to 50 mg proteins. Probe substrate final assay concentrations and
incubation times were as follows: bilirubin, 10 mM, 10 minutes; deferiprone,
20 mM, 60 minutes; propofol, 50 mM, 30 minutes; AZT, 500 mM, 60 minutes;
MPA, 100 mM, 60 minutes; tacrolimus, 200 mM, 60 minutes; sorafenib, 200 mM,
60 minutes. Glucuronide products were measured by mass spectrometry-based
methods as described (Lepine et al., 2004; Thibaudeau et al., 2006; Belanger
et al., 2009).
Statistical Analysis. Statistical significance between normal and tumor kid-
neys for UGT protein concentration, mRNA expression levels, and glucuronidation
activity was determined by a paired Mann-Whitney statistical test (*P # 0.05;
**P # 0.01; ***P # 0.001) using GraphPad Prism (GraphPad Software,
La Jolla, CA). Statistical correlation scores between protein concentration, mRNA
expression levels and activity were determined by a Spearman correlation test
using XLSTAT (Addinsoft, New York, NY).
Results
Quantitative Profiling of UGTs in Human Kidney Tissues
UGT Protein Concentration in Normal and Tumor Kidneys
Measured by Mass Spectrometry. Signature peptides specific to each
UGT were used to determine expression levels of UGTs in 10 normal
and 11 tumoral tissues. Based on absolute protein concentrations,
UGT1A9, UGT2B7, and UGT1A6 were the predominant UGT proteins
expressed in both normal and tumoral kidney tissues (Fig. 1A). The
relative abundance of UGT1A9 and UGT2B7 was considerably reduced
between normal and tumoral tissues (Figs. 1A and 2A). The average
concentrations of UGT2B7 and UGT1A9 in normal kidney homoge-
nates were 3.6 and 7.5 pmol/mg proteins, respectively. However, 4.9
(P = 0.007)- and 2.5 (P = 0.06)-fold lower concentrations were found in
kidney tumor tissues versus normal tissues, whereas UGT1A6 levels
remained unchanged (P = 0.46) (Figs. 1A and 2A; Table 1). Of note,
UGT1A10 was detected in two tumor samples. UGT1A3, 1A4, 1A5,
1A7, 1A8, 2B4, 2B10, 2B15, and 2B17 were below limits of detection
Fig. 2. Relative UGT expression in normal and tumoral kidneys.
(A) Relative protein concentrations of quantified UGTs in normal
and tumoral kidneys, based on average concentrations from data
shown in Fig. 1A and Tables 1 and 2. (B) Relative UGT mRNA
expression in normal and tumoral kidneys based on reverse
transcription-quantitative PCR quantification data shown in Fig.
1B and Tables 1 and 2.
TABLE 1
UGT protein concentrations in normal and tumor kidney homogenates
UGT
Normal Tumor
UGT positive tissuesa Min Max Average S.D. ALT CVb CV UGT positive tissues Min Max Average S.D. ALT CV CV
% pmol/mg proteins % % pmol/mg proteins %
1A6 100 0.30 1.97 0.58 0.50 85 85 72 0.00 2.48 0.59 0.71 93 120
1A9 80 0.00 17.00 7.53 6.16 63 81 54 0.00 11.27 3.05 4.06 71 133
2B7 90 0.00 7.05 3.62 2.62 60 72 45 0.00 3.72 0.74 1.27 97 170
a% Tissues with levels above limit of detection.
b% Alternative (ALT) coefficients of variation (CV), calculated for tissues above limit of detection.
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or undetected. In both normal and tumoral tissues, interindividual
variability was notable, especially for UGT1A9, for which five
individuals expressed levels above 10 pmol/mg proteins whereas five
others had low or undetectable levels.
UGT mRNA Levels in Normal and Tumor Kidneys. UGTs
detected in kidneys by targeted mass spectrometry were also assessed by
quantitative PCR of reverse-transcribed mRNA isolated from the same
kidney samples. For UGT1 transcripts, this quantification was based on
the specific amplification of exons 1. For UGT2B7, the strategies relied
on amplification of exons 2 and 3, present in all known variants.
Interindividual variability observed at the protein concentration level
was also a prominent feature of UGT mRNA expression (Fig. 1B).
Relative quantification of UGT mRNA expression indicates that in both
normal and tumoral kidney tissues, UGT1A6, UGT1A9, and UGT2B7
were the predominant mRNA species (Figs. 1B and 2B). UGT1A3 and
UGT1A7 were also expressed at a low but appreciable level (Fig. 2B;
Table 2). In line with UGT protein concentrations, the relative amount
of all UGT mRNAs was reduced in tumor samples, in particular
UGT1A9 (Fig. 1B, Table 2).
UGT-Specific Glucuronidation Activity and Relationship with
Protein and mRNA Levels. Glucuronidation activity in kidney tissues
was assessed using probe substrates for several UGTs, including
tacrolimus (UGT1A4), deferiprone (UGT1A6) (Benoit-Biancamano
et al., 2009), propofol, sorafenib, and mycophenolic acid (UGT1A9),
and zidovudine or AZT (UGT2B7). Conjugating activity was measured in
12 normal and 14 tumoral kidney tissues. Glucuronidation of tacrolimus
was not detected in any kidney samples, in line with the undetected
UGT1A4 protein by mass spectrometry. Glucuronidation activity was
TABLE 2
Expression levels of UGT mRNAs in normal and tumor kidneys
Gene
Normal Tumor
Min Max Average S.D. CV Min Max Average S.D. CV
RQ  103 % RQ  103 %
UGT1A1 96 1991 759 619 82 65 1037 338 306 91
UGT1A3 261 4893 2113 1598 76 29 1964 621 570 92
UGT1A6 1580 37112 13385 10,234 76 155 19197 5555 6057 109
UGT1A7 231 12264 4686 4229 90 44 4797 1194 1609 135
UGT1A8 107 1071 487 342 70 52 18821 1751 5377 307
UGT1A9 488 216460 39942 63346 159 72 67481 15440 21298 138
UGT1A10 136 991 473 354 75 22 4787 670 1393 208
UGT2B7 (ex1–2) 232 44548 10597 15760 149 45 11058 2387 3419 143
UGT2B7 (ex2–3) 2506 41922 11852 14001 118 122 15154 6847 4210 61
CV, coefficients of variation; RQ, relative quantity; ex, exons.
Fig. 3. Glucuronidation is impaired in tumor kidneys. Glucuronidation activity in normal and tumoral kidney homogenates for deferiprone (A), propofol (B), sorafenib (C),
mycophenolic acid (D) (specifically the formation of MPA-G), and zidovudine (E). N, normal kidneys homogenates (n = 12),s; T, tumoral kidney homogenates (n = 14),d.
Paired normal and tumoral samples are connected with a black line. Coefficients of variation (CV) among normal and tumoral samples are given. Detailed quantification data
are given in Table 3. **P#0.01; ***P#0.001; N.S. not significant.
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detected for all other substrates, as expected from the expression levels of
the UGTs responsible for conjugating each substrate (Fig. 3; Table 3).
The glucuronidation activity of UGT1A6 (deferiprone) was similar
between normal and tumor kidney tissues (Fig. 3A) and correlated well
with protein concentrations (Fig. 4B). However, mRNA levels correlated
with UGT1A6 protein concentration and activity only in tumor tissues
and not in normal tissues (Fig. 4, A and C). Glucuronidation of UGT1A9
substrates propofol, sorafenib, and MPA were significantly reduced in
kidney tumors, by 7.6-, 5.2-, and 6.4-fold. respectively, relative to normal
tissues (Fig. 3, B–D). This decreased glucuronidation capacity is further
emphasized when only paired normal and tumor samples are considered
(sorafenib, 10.3-fold, P = 0.01; propofol, 8.7-fold, P = 0.008; MPA, 9.0-
fold, P = 0.02). There were significant correlations between UGT1A9
metabolism of propofol, MPA, and sorafenib and UGT1A9 protein
concentration and mRNA levels, in both normal and tumor kidney tissues
(Fig. 5). Glucuronidation of AZT (UGT2B7 substrate) was the most
drastically impaired in tumor relative to normal kidney tissues, with a
96-fold overall decrease and a 148-fold decrease (P = 0.002) for paired
tissues (Fig. 3E). The concentration of UGT2B7 protein correlated
significantly with AZT glucuronidation in both normal and tumor kidney
tissue samples (Fig. 6A). On the other hand, UGT2B7 activity correlated
with mRNA levels only in normal kidney tissues and only when UGT2B7
mRNA levels were measured by a strategy assessing the classic exon 1
comprised in mRNA transcripts encoding the UGT2B7 enzyme (Fig.
6D). There was a lack of correlation between mRNA levels assessed by
a global strategy targeting exons 2–3 (common to all mRNA transcripts
derived from the UGT2B7 gene) and AZT glucuronidation (Fig. 6E) or
UGT2B7 protein concentration (Fig. 6C) in both normal and tumoral
tissues. UGT2B7 mRNA levels determined by the exons 1–2 strategy
correlated with UGT2B7 protein concentration only in tumor tissues
(Fig. 6B).
Discussion
This study portrays UGT expression and glucuronidation activity in
the kidney and addresses for the first time the difference in UGT
expression and activity between normal and tumor kidney tissues (Fig.
7). In both normal and tumor kidneys, UGT1A9 mRNA and protein
levels predominate, and this is well reflected by the high conjugating
capacity of its probe substrates propofol as well as the anticancer agent
sorafenib. UGT2B7 is a major expressed and active UGT enzyme only
in normal kidneys. This high UGT1A9 and UGT2B7 expression is in
line with previous reports based on mRNA expression levels and
protein concentrations in normal kidney microsomes (Nakamura et al.,
2008; Ohno and Nakajin, 2009; Harbourt et al., 2012; Fallon et al.,
2013a; Sato et al., 2014). We also observed that all individuals
expressed low but significant amounts of UGT1A6 and conjugating
activity toward the probe substrate deferiprone (Benoit-Biancamano
et al., 2009). All kidney samples were devoid of UGT1A1 expression,
TABLE 3
Glucuronidation activity of kidney homogenate samples for listed probe substrates
Substrate
Normal Tumor
Min Max Average S.D. CV Min Max Average S.D. CV
% %
Deferiprone-G (nmol/min per mg) 0.7 6.2 1.7 1.5 86 0.01 2.4 1.1 0.8 69
Propofol-G (area/min per mg) 0.2 7.5 3.1 2.2 69 0.01 1.5 0.4 0.4 109
Sorafenib-G (area/min per mg) 33 19133 6558 5940 91 0 8083 1257 2295 183
MPA-G (pmol/min per mg) 1.0 318 147 106 72 0.1 104 23 31 134
AZT-G (pmol/min per mg) 0.01 102.0 35.1 31.4 89 0.00 2.2 0.4 0.6 160
CV, coefficients of variation.
Fig. 4. Correlation between UGT1A6 protein and mRNA levels (A); protein levels
and deferiprone glucuronidation activity (B); mRNA levels and deferiprone
glucuronidation activity (C) in normal (N, d) and tumor (T, u) kidneys. The
correlation coefficients r2 were determined using a Spearman correlation test. N.S., not
significant.
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supported by a lack of bilirubin-conjugating activity. These findings
are in agreement with previous mRNA (Nakamura et al., 2008; Ohno
and Nakajin, 2009) and absolute protein quantification analyses
(Fallon et al., 2013a). None of the individuals expressed UGT1A4,
based on protein levels and activity toward the probe substrate
tacrolimus, in contrast to previous mRNA quantifications (Nakamura
et al., 2008; Ohno and Nakajin, 2009). All expressed kidney UGTs
displayed a high degree of interindividual variability, as previously
Fig. 5. Correlation between UGT1A9 protein and mRNA levels (A); mRNA levels and glucuronidation activity of propofol (B), sorafenib (D), and mycophenolic acid (F);
protein levels and glucuronidation activity of propofol (C), sorafenib (E), and mycophenolic acid (G) in normal (N, d) and tumor (T, ⬜) kidneys. The correlation
coefficients r2 were determined using a Spearman correlation test. N.S., not significant.
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observed in other drug metabolizing tissues. Some variability may
arise from the sex of the donors, which could not be taken into account
due to the limited number of individuals, as well as from the site of
biopsy sampling, because the kidney is characterized by a structural
heterogeneity that is paralleled by variable UGT expression within the
kidney structures (Gaganis et al., 2007; Knights and Miners, 2010;
Bellemare et al., 2011).
Our study further reports the first assessment of UGT expression
and activity in kidney tumor tissues. It demonstrates a drastically
reduced conjugation capacity of kidney tumors for propofol, sorafenib,
MPA, and zidovudine, owing to considerably decreased UGT1A9 and
UGT2B7 gene and protein expression in tumor relative to normal
tissues. In contrast, UGT1A6 protein expression and activity were
similar in normal and tumor kidney tissues. This analysis included
paired peritumoral and tumoral tissues, enhancing the strength of this
assessment. We also establish that the glucuronidation of the tyrosine
kinase inhibitor sorafenib is significantly reduced in tumors compared
with normal kidney tissues. The decreased glucuronidation activity of
kidney tumors relative to normal tissues is of particular relevance in
advanced renal clear cell carcinoma treatment strategies, given that
sorafenib is an important renal carcinoma anticancer agent (Escudier
et al., 2007; Zustovich et al., 2011). It is primarily metabolized by
CYP3A4 and UGT1A9 in the liver, but its renal metabolism has not
been assessed (Keating and Santoro, 2009; Ye et al., 2014). The
biologic impact of locally reduced glucuronidation capacity in
diseased tissues remains to be examined but could be of clinical
relevance to susceptibility to kidney cancer or treatment of kidney
cancer. The important loss of UGT1A9- and UGT2B7-conjugating
activity in tumor kidneys is in line with the reduced expression of
several UGT1A and UGT2B7 observed at both mRNA and protein
levels in hepatocellular carcinomas (Strassburg et al., 1997; Yan et al.,
2014; Ye et al., 2014), UGT1A10 and UGT2B7 in breast cancer
Fig. 6. Correlation between UGT2B7 protein concentration and zidovudine glucuronidation activity (A); mRNA and protein levels (B, C); mRNA levels and zidovudine
glucuronidation activity (D, E) in normal (N, d) and tumor (T, ⬜) kidneys. mRNA levels were determined for all variants using an exon 2–3 amplification strategy (B and
C) or only for active variants using an exon 1-2 strategy (D and E). The correlation coefficients r2 were determined using a Spearman correlation test. N.S., not significant.
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tissues (Starlard-Davenport et al., 2008), as well as UGT2B7 mRNA
and glucuronidation activity in kidney tumors (Menard et al., 2013).
However, some UGTs (UGT1A, UGT2B7, UGT2B15, and UGT2B17)
are increased in other types of cancers, including those from the
endometrium and in patients with acute myeloid leukemia and chronic
lymphocytic leukemia, and emerge as a feature associated with drug
resistance (Lepine et al., 2010; Dellinger et al., 2012; Gruber et al.,
2013; Zahreddine et al., 2014), supporting the relevance to develop
analytical tools that accurately establish the glucuronidation activity of
various tissues.
Although our absolute quantification of UGT proteins was conducted
in kidney homogenates, they are well in line with previous reports that
assessed UGT concentrations in normal kidney microsomes (Harbourt
et al., 2012; Fallon et al., 2013a; Sato et al., 2014). Indeed, UGT1A9
protein concentration is 13.0-fold and 2.1-fold higher than UGT1A6 and
UGT2B7, respectively, as observed by others (Fallon et al., 2013a; Sato
et al., 2014). Our absolute quantification of UGTs in kidney homo-
genates generally lies in the 10% range of that measured in microsomes
by others, consistent with the lower UGT protein concentration mea-
sured in human liver S9 fractions being 10–15% that of liver microsomes
(Fallon et al., 2013b). Therefore, in our study, the use of homogenates
may have limited the quantitative assessment of minor UGTs such as
UGT1A5, previously detected in human kidney microsomes (Harbourt
et al., 2012), and of UGT1A10, which were detected in two kidney
samples in our study. However, actual tissue samples from patients with
diseases of interest are potentially of higher translational relevance.
As previously reported for several UGTs in other organs, there is
a clear discrepancy between mRNA expression and protein concen-
tration or UGT activity, supporting that posttranscriptional events are
important modulators of UGT protein expression and activity. This
has been highlighted in previous studies addressing alternative
splicing of UGT mRNA transcripts. For instance, our previous work
supports that alternative splicing modulates UGT2B7 activity, as there
was a good correlation between exon 1–containing mRNA levels and
conjugating activity in normal kidney tissues but not with total mRNA
levels (assessed by an exons 2–3 strategy) (Fig. 6). The correlation
with exon 1–containing mRNAs was lost in tumoral kidney tissues,
indicating that alternative splicing or other posttranscriptional events
are occurring, as previously proposed (Menard et al., 2013). On the
other hand, protein concentrations correlated well with activity for
most abundant enzymes, indicating that absolute protein quantification
is therefore a good surrogate for predicting the activity of UGT1A6,
UGT1A9, and UGT2B7.
In conclusion, this study characterized for the first time UGT
mRNA, protein, and enzymatic activity in normal and tumor kidneys
and reveals that the predominant UGTs in normal kidneys, namely
UGT1A9 and UGT2B7, are significantly reduced in tumor tissues
(Fig. 7). Our observations highlight that the glucuronidating activity of
tumor tissues, such as for the anticancer agent sorafenib, is strongly
suppressed relative to normal tissues, with potential impact on tumor
response or adverse effects. It further documents a high interindividual
variability in the expression of UGTs and in particular for UGT1A9.
The regulation of UGT and glucuronidation in kidneys remains to be
examined, but our study pinpoints posttranscriptional events such as
alternative splicing as important contributors of this variability in
normal tissues. Nonetheless, the mechanism resulting in the repression
of UGT expression and activity in tumorigenic tissues remains to be
characterized.
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